ロード中...
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent yea...
保存先:
| 出版年: | Theranostics |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ivyspring International Publisher
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6299695/ https://ncbi.nlm.nih.gov/pubmed/30613284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.30357 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|